Table 4.
Analysis of allelic association between SCN4B variant p.Gly8Ser and VT
| Cohort | Sample size (case/control) | R.A. frequency (case/control) | PHWE | Without adjustment | With adjustmenta | ||
|---|---|---|---|---|---|---|---|
| Pobs | OR (95% CI) | Padj | OR (95% CI) | ||||
| VT cohort 1 | 299/981 | 1.84%/0.20% | 1 | 5.58E – 05 | 9.17 (2.91–28.91) | 1.21E – 04 | 11.04 (3.24–37.54) |
| VT cohort 2 | 270/639 | 1.67%/0.39% | 1 | 4.47 E – 03 | 4.31 (1.44–12.94) | 0.033 | 3.62 (1.11–18.12) |
| combined | 569/1620 | 1.76%/0.28% | 1 | 1.20E – 07 | 6.42 (2.92–14.15) | 3.09E – 05 | 6.17 (2.62–14.53) |
| IVT | 298/1620 | 1.85%/0.28% | 1 | 1.04E – 06 | 6.75 (2.79–16.36) | 1.89E – 05 | 7.27 (2.93–18.06) |
R.A. risk allele, IVT idiopathic VT without structural heart disease, coronary artery disease, cardiomyopathies, valvular disease, hypertension, heart failure, and rheumatic heart disease, PHWE P value for Hardy–Weinberg disequilibrium test, Pobs P value observed, i.e., uncorrected P value by a Fisher’s exact test, Padj P value after adjustment with age and sex by multivariate logistic regression analysis for potential confounders, OR odds ratio, 95% CI 95% confidence interval
a
P value after adjustment of age and sex by multivariate logistic regression analysis